With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk trades at a significant discount to Eli Lilly, offering nearly 38% upside. Click here to find out why NVO stock ...

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

Novo Nordisk (NVO 0.46%), a Danish pharmaceutical company, is the developer of Ozempic, which is often referred to as a weight-loss drug.But there is actually a nuance, albeit an important one, to ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

In what Science magazine has dubbed “Novo Nordisk’s Canadian Mistake,” Ozempic is soon to come off patent in Canada, opening ...

Ongoing patent battle between Novo Nordisk and Dr Reddy’s Laboratories over semaglutide export to multiple countries.

Novo Nordisk on Thursday surpassed Tesla in market valuation after the maker of the popular weight-loss drug Wegovy and Ozempic announced positive early trial data for a highly anticipated new ...

LONDON, May 2 (Reuters) – Novo Nordisk has seen the price of its hugely popular weight-loss drug Wegovy and diabetes drug Ozempic fall in the United States as volumes and competition have ...

Diabetes drug Ozempic, along with its sibling product Wegovy, has provided a massive tailwind for Novo Nordisk (NVO-1.39%) this year as people grab at weight loss options. The pharma stock has ...

As the Ozempic craze pushes advancements in weight-management medicine forward, pharmaceutical company Novo Nordisk, the company behind the so-called “miracle-drug,” is continuing to crack ...

Novo Nordisk's blockbuster diabetes drug Ozempic may reduce the risk of developing Alzheimer's disease, suggesting its potential to delay or prevent the memory-robbing condition, according to a ...